Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK5764227 in Recurrent Grade 4 Glioma and Brain Metastases
NCT07268053Phase 1Recruiting
- Sponsor
- Ivy Brain Tumor Center
- Start
- Feb 2026
- Primary completion
- Jul 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of risvutatug rezetecan in glioblastoma (GBM) and brain metastases (2 arms), sponsored by Ivy Brain Tumor Center. Primary endpoints: Total, Cleaved, and Unbound GSK5757810 Payload Concentration in Tumor Tissue and Incidence of Adverse Events as Assessed by CTCAE v5.0. Started Feb 2026; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
glioblastoma (GBM)brain metastases
Beyond the preview
Go deeper on NCT07268053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268053.